武警医学
武警醫學
무경의학
MEDICAL JOURNAL OF THE CHINESE PEOPLE'S ARMED POLICE FORCES
2014年
9期
905-907
,共3页
急性冠脉综合征%阿托伐他汀%基质金属蛋白酶-9%白介素-18
急性冠脈綜閤徵%阿託伐他汀%基質金屬蛋白酶-9%白介素-18
급성관맥종합정%아탁벌타정%기질금속단백매-9%백개소-18
acute coronary syndrome%atorvastatin%matrix metalloproteinase-9%interleukin-18
目的：探讨阿托伐他汀对急性冠脉综合征（acute coronary syndrome，ACS）患者血清基质金属蛋白酶-9（matrix metalloproteinase-9，MMP-9）、白介素-18（interleukin-18，IL-18）水平的影响。方法将ACS患者60例随机分为阿托伐他汀组（阿托伐他汀20 mg/d，连续用药14 d）和对照组（除未用阿托伐他汀外，余治疗同阿托伐他汀组）。药物治疗前及治疗14 d后检测血清MMP-9、IL-18水平。结果阿托伐他汀组治疗后MMP-9及IL-18[分别是（295±110） mg/L和（399±115） pg/ml]与治疗前[分别是（368±97） mg/L和（471±105） pg/ml]比较有下降，差异均有统计学意义（ P＜0．05）；阿托伐他汀组治疗后MMP-9及IL-18水平均明显低于同期对照组[分别是（358±95） mg/L和（466±109） pg/ml]，差异有统计学意义（P＜0．05）。结论阿托伐他汀可降低ACS 患者血清MMP-9、IL-18水平，抑制斑块内炎性反应，促进斑块的稳定性。
目的：探討阿託伐他汀對急性冠脈綜閤徵（acute coronary syndrome，ACS）患者血清基質金屬蛋白酶-9（matrix metalloproteinase-9，MMP-9）、白介素-18（interleukin-18，IL-18）水平的影響。方法將ACS患者60例隨機分為阿託伐他汀組（阿託伐他汀20 mg/d，連續用藥14 d）和對照組（除未用阿託伐他汀外，餘治療同阿託伐他汀組）。藥物治療前及治療14 d後檢測血清MMP-9、IL-18水平。結果阿託伐他汀組治療後MMP-9及IL-18[分彆是（295±110） mg/L和（399±115） pg/ml]與治療前[分彆是（368±97） mg/L和（471±105） pg/ml]比較有下降，差異均有統計學意義（ P＜0．05）；阿託伐他汀組治療後MMP-9及IL-18水平均明顯低于同期對照組[分彆是（358±95） mg/L和（466±109） pg/ml]，差異有統計學意義（P＜0．05）。結論阿託伐他汀可降低ACS 患者血清MMP-9、IL-18水平，抑製斑塊內炎性反應，促進斑塊的穩定性。
목적：탐토아탁벌타정대급성관맥종합정（acute coronary syndrome，ACS）환자혈청기질금속단백매-9（matrix metalloproteinase-9，MMP-9）、백개소-18（interleukin-18，IL-18）수평적영향。방법장ACS환자60례수궤분위아탁벌타정조（아탁벌타정20 mg/d，련속용약14 d）화대조조（제미용아탁벌타정외，여치료동아탁벌타정조）。약물치료전급치료14 d후검측혈청MMP-9、IL-18수평。결과아탁벌타정조치료후MMP-9급IL-18[분별시（295±110） mg/L화（399±115） pg/ml]여치료전[분별시（368±97） mg/L화（471±105） pg/ml]비교유하강，차이균유통계학의의（ P＜0．05）；아탁벌타정조치료후MMP-9급IL-18수평균명현저우동기대조조[분별시（358±95） mg/L화（466±109） pg/ml]，차이유통계학의의（P＜0．05）。결론아탁벌타정가강저ACS 환자혈청MMP-9、IL-18수평，억제반괴내염성반응，촉진반괴적은정성。
Objective To investigate the effect of atorvastatin on plasma MMP-9 and IL-18 in patients with acute coronary syn-drome ( ACS ) .Methods Sixty patients with ACS were randomly divided into treatment group ( taking atorvastatin 20 mg/d for 14 days), control group (no atorvastatin, other treatments were similar to treatment group ).Before drug therapy and after 14 days, MMP-9 and IL-18 levels in serum were measured .Results Compared with pre-treatment, the levels of MMP-9 and IL-18 in treatment group were decreased [(295 ±110)mg/L vs(358 ±95)mg/L;(399 ±115)pg/ml vs(471 ±105)pg/ml ,respectively],these differences were statistically significant (P<0.05).Moreover, the levels of MMP-9 and IL-18 in treatment group were significantly lower than those in control group [(358 ±95)mg/L,(466 ±109)pg/ml, respectively], these differences were statistically significant (P<0.05).Conclu-sions Atorvastatin can decrease serum MMP-9 and IL-18 levels in patients with ACS , which contributes to inhibit plaque inflammation , to advance the stability of plaque .Early intensive atorvastatin treatment may yield more significant benefits to the patients with ACS .
